Technologies - Icosagen

Menu

Search from website

Home Technologies

Technologies

Ask for a quote:

HybriFree Technology

Our HybriFree Technology is based on B-cell cloning and used for efficient discovery of monoclonal antibodies from immunized chickens and rabbits, ready for their immediate production in mammalian cells. HybriFree antibody discovery is rapid, flexible and effective. It can also be used for cloning antibodies from recovered patients’ PBMCs or from existing hybridomas.

QMCF Technology

Our QMCF Technology is a proprietary, fast, and reliable transient mammalian expression system for recombinant protein production with high yields of up to 1g/L. QMCF-made recombinant proteins are suitable for pre-clinical in vivo & in vitro studies, structural biology, drug discovery and as well as for commercial diagnostic assays.

IcoCell Technology

IcoCell is a proprietary platform to efficiently generate CHO-based stable high producer cell lines. These serve for large-scale GMP-compliant production of therapeutic recombinant proteins and monoclonal antibodies, both for clinical trial materials as well as for commercial production afterwards.

HPV assay

Icosagen has developed a specific 3D cell-based assay to identify human papillomavirus (HPV) DNA replication inhibitors in high-throughput format. In a proof of concept (PoC) study, 5 high-risk HPV specific inhibitors were identified that influence Tdp1 dependent DNA repair.

EU projects and R&D Collaboration

Icosagen participates in several international and national research programmes and projects.

HybriFree Technology

Our HybriFree Technology is based on B-cell cloning and used for efficient discovery of monoclonal antibodies from immunized chickens and rabbits, ready for their immediate production in mammalian cells. HybriFree antibody discovery is rapid, flexible and effective. It can also be used for cloning antibodies from recovered patients’ PBMCs or from existing hybridomas.

QMCF Technology

Our QMCF Technology is a proprietary, fast, and reliable transient mammalian expression system for recombinant protein production with high yields of up to 1g/L. QMCF-made recombinant proteins are suitable for pre-clinical in vivo & in vitro studies, structural biology, drug discovery and as well as for commercial diagnostic assays.

IcoCell Technology

IcoCell is a proprietary platform to efficiently generate CHO-based stable high producer cell lines. These serve for large-scale GMP-compliant production of therapeutic recombinant proteins and monoclonal antibodies, both for clinical trial materials as well as for commercial production afterwards.

HPV assay

Icosagen has developed a specific 3D cell-based assay to identify human papillomavirus (HPV) DNA replication inhibitors in high-throughput format. In a proof of concept (PoC) study, 5 high-risk HPV specific inhibitors were identified that influence Tdp1 dependent DNA repair.

EU projects and R&D Collaboration

Icosagen participates in several international and national research programmes and projects.

HybriFree Technology

Our HybriFree Technology is based on B-cell cloning and used for efficient discovery of monoclonal antibodies from immunized chickens and rabbits, ready for their immediate production in mammalian cells. HybriFree antibody discovery is rapid, flexible and effective. It can also be used for cloning antibodies from recovered patients’ PBMCs or from existing hybridomas.

QMCF Technology

Our QMCF Technology is a proprietary, fast, and reliable transient mammalian expression system for recombinant protein production with high yields of up to 1g/L. QMCF-made recombinant proteins are suitable for pre-clinical in vivo & in vitro studies, structural biology, drug discovery and as well as for commercial diagnostic assays.

IcoCell Technology

IcoCell is a proprietary platform to efficiently generate CHO-based stable high producer cell lines. These serve for large-scale GMP-compliant production of therapeutic recombinant proteins and monoclonal antibodies, both for clinical trial materials as well as for commercial production afterwards.

HPV assay

Icosagen has developed a specific 3D cell-based assay to identify human papillomavirus (HPV) DNA replication inhibitors in high-throughput format. In a proof of concept (PoC) study, 5 high-risk HPV specific inhibitors were identified that influence Tdp1 dependent DNA repair.

EU projects and R&D Collaboration

Icosagen participates in several international and national research programmes and projects.

Latest news

MART USTAV JR.: The Pandemic That Brought Science Home

19.09

->

PUBLICATION: Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates

06.09

->

Our location

United States Office

77 Geary St. 5th Floor
San Francisco, CA 94108
+1 415 548 6625

European Office

Eerika tee 1
Õssu, Kambja vald
Tartu maakond 61713
Estonia
+372 737 7070

© 2023 Icosagen